Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic breast cancers.
- Author:
Zhi-kuan WANG
1
;
Hai-yan MENG
;
Chun HAN
;
Jun-lan YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Breast Neoplasms; metabolism; pathology; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; metabolism; Prognosis; Receptor, ErbB-2; metabolism; Vascular Endothelial Growth Factor A; metabolism
- From: Acta Academiae Medicinae Sinicae 2010;32(4):403-406
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expressions of human epidermal growth factor receptor 2 (Her-2) and vascular endothelial growth factor (VEGF) in primary and recurrent metastatic breast cancers and explore their relationship.
METHODSThe expressions of Her-2 and VEGF in 60 primary and recurrent metastatic breast cancers were detected using immunohistochemical methods. Their relationship was analyzed.
RESULTSThe positive rates of Her-2 and VEGF in the recurrent metastatic breast cancer were 40.00% and 53.33%, respectively, which were significantly higher than that in the primary breast cancer (18.33% and 31.67%) (P < 0.05). The total diversify rates of Her-2 and VEGF were 28.33% and 35.00%, respectively. Her-2 and VEGF expressions were significantly correlated between the primary and the recurrent metastatic breast cancers( P < 0.05).
CONCLUSIONSHer-2 and VEGF may play synergic roles in the occurrence and development of breast cancer. Over-expressions of Her-2 and VEGF predict poor prognosis.
